Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported its second-quarter 2025 results, showcasing clinical progress in gene therapy, new strategic partnerships, and a planned spin-off to sharpen its business focus. …
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has expanded its Retina Scientific Advisory Board (SAB) and executive leadership team as the company accelerates toward filing three Biologics License Applications (BLAs) …
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating OCU410ST, a gene therapy candidate designed …
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy Read More PHILADELPHIA, PA & MALVERN, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) and OrthoCellix, Inc. have announced a definitive merger agreement to combine the two companies in an all-stock transaction. The …
Carisma Therapeutics and OrthoCellix Merge to Advance Regenerative Cell Therapy for Orthopedic Diseases Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 pivotal confirmatory trial of OCU410ST, an innovative …
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced its participation in the 2025 BIO International Convention, held from June 16-19 at the Boston Convention & Exhibition Center. The biopharmaceutical company …
Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has signed a binding term sheet with a prominent pharmaceutical and healthcare company in Korea, granting exclusive Korean rights to OCU400, its experimental …
Ocugen Secures Licensing Agreement for OCU400 in Korea Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for its investigational therapy OCU410ST, aimed …
Ocugen Receives Rare Pediatric Disease Designation for OCU410ST Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reported its first-quarter 2025 financial results and shared updates on its growing pipeline of gene therapy treatments aimed at combating significant unmet …
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will highlight its pioneering modifier gene therapy platform at two major industry events in May 2025. The company will present its clinical advancements …
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences Read More